<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4081">
  <stage>Registered</stage>
  <submitdate>1/06/2010</submitdate>
  <approvaldate>1/06/2010</approvaldate>
  <nctid>NCT01940198</nctid>
  <trial_identification>
    <studytitle>Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia</studytitle>
    <scientifictitle>Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia</scientifictitle>
    <utrn />
    <trialacronym>REfLecT</trialacronym>
    <secondaryid>AI424-417 ST</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of HIV-1 infected participants with atazanavir experience - Proportion of patients who continue on atazanavir for 2 years or greater from baseline to termination/current.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of HIV-1 infected participants with atazanavir experience - 1. Therapeutic efficacy of atazanavir</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of HIV-1 infected participants with atazanavir experience - Tolerability to atazanavir</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of HIV-1 infected participants with atazanavir experience - ART treatment history</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of HIV-1 infected participants with atazanavir experience - contraindicated therapy</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. HIV-1 positive

          2. Have commenced ATV between 2002-2008 (Baseline)

          3. Follow-up data (clinical and laboratory) available from baseline</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients not commenced ATV between 2002-2008

          2. No follow-up data (clinical and laboratory) available from baseline

          3. Patient 'lost to follow-up' with &lt; 2 years of follow-up data (Clinical and laboratory)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>117</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Holdsworth House Medical Practice - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Holdsworth House Medical Practice</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bristol-Myers Squibb</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This observational study will aim to determine long-term atazanavir experience in a high HIV
      caseload primary care practice in Sydney, Australia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01940198</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark Bloch, Dr.</name>
      <address>Holdsworth House Medical Practice</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>